Given India's position as a global generic-drug supplier, examine the importance of advances in asymmetric synthesis for India's pharmaceutical self-reliance.

India is the world's third-largest pharmaceutical producer by volume. Yet for some bulk drugs it imports 80–100% of what it needs [2]. The 2026 Chemistry Nobel went to Henri Kagan and Kenso Soai for non-linear effects and autocatalysis in asymmetric synthesis [1]. It matters here because it makes "single-handed" drug molecules easier and cheaper to make.

Why asymmetric synthesis matters for medicines

• Chirality: many drug molecules exist as two mirror-image forms (enantiomers). Usually only one form heals. The other may be inactive or harmful, as the thalidomide tragedy showed.
• Ordinary reactions give a 50:50 racemic mix. Separating the two forms wastes material and raises cost.
• Kagan's non-linear effect (1986) showed that an impure catalyst can still give a highly pure product. Soai's autocatalysis showed that a product can amplify its own handedness. Both have been decisive for designing drug-making reactions [1].

Importance for India's self-reliance

• Import substitution: in 2024-25 India imported about USD 4.35 billion of APIs, bulk drugs and intermediates, about 73.7% from China [3]. Single-enantiomer intermediates are among the hardest of these to make at home.
• Cost competitiveness: cheaper catalysts and less waste lower the cost of chiral APIs. This matters most for low-margin generics.
• Quality and exports: purer products make it easier to meet strict regulators in the markets India exports to.
• Moving up the value chain: India gains process-chemistry know-how, not just the ability to assemble formulations.

Gaps that remain

• The PLI scheme for bulk drugs (₹6,940 crore over eight years) rewards output, not new chemistry [2].
• 32 completed projects have added 56,679 MT a year of capacity [4]. Tonnage does not show whether chiral molecules are being made in India.
• Turning a laboratory breakthrough into a plant-scale process needs sustained R&D, which a production subsidy alone does not create.

Asymmetric synthesis connects frontier chemistry with India's drug security. The Department of Pharmaceuticals could track chiral intermediates as a separate category under PLI. DST and CSIR could fund university–industry projects in asymmetric catalysis. Together these would make the "pharmacy of the world" truly self-reliant and advance SDG 3 by making safe, affordable medicines available.